Crinetics Reports $10.3M Palsonify Sales Amid 232 Enrollment Updates

Key Takeaways

• Palsonify (paltusotine) generated $10.3 million in Q1 2026 net product revenue, up 91% from $5.4 million in Q4 2025, according to Crinetics' SEC filing.
• FDA approved Palsonify on September 25, 2025, for adults with acromegaly who had inadequate response to surgery or for whom surgery is not an option (FDA announcement).
• 232 enrollment forms were submitted during Q1 2026, indicating continued patient uptake.
• Approximately 70% of patients on Palsonify were on reimbursed therapy by quarter-end, improving access.
• Crinetics holds $1.3 billion in cash and investments as of March 31, 2026, funding ongoing development.

What Are Palsonify's Q1 2026 Financial Results?

Crinetics Pharmaceuticals reported total revenue of $10.7 million for Q1 2026, compared to $0.4 million in Q1 2025. This dramatic increase reflects the successful commercial launch of Palsonify following its FDA approval in September 2025.

Net product revenue from Palsonify reached $10.3 million, representing a 91% increase from the $5.4 million reported in Q4 2025. Cost of product revenue was $0.2 million, primarily related to distribution and packaging.

What Is Palsonify and How Does It Work?

Palsonify (paltusotine) is an oral, non-peptide somatostatin receptor ligand approved by the FDA for the treatment of acromegaly. The drug works by binding to somatostatin receptor subtype 2 (SSTR2), inhibiting growth hormone (GH) secretion.

Unlike traditional peptide somatostatin analogs that require injection, Palsonify offers an oral dosing option. The drug is indicated for adults with acromegaly who have had an inadequate response to surgery or for whom surgery is not an option.

What Is Acromegaly?

Acromegaly is a rare, serious endocrine disorder caused by excessive growth hormone (GH) production, typically from a pituitary adenoma. The condition affects approximately 14,000 to 26,000 adults in the United States.

Untreated acromegaly leads to significant morbidity and mortality. Current treatment options include surgery, radiation therapy, and pharmacologic interventions such as somatostatin analogs, dopamine agonists, and growth hormone receptor antagonists.

What Clinical Evidence Supports Palsonify?

Palsonify's approval was supported by the ACROBAT clinical trial program. The pivotal Phase 3 trial, NCT04837040, evaluated the safety and efficacy of paltusotine in patients with acromegaly. The randomized, placebo-controlled study demonstrated statistically significant reductions in insulin-like growth factor 1 (IGF-1) and growth hormone levels.

Earlier Phase 2 trials, including ACROBAT Edge (NCT03789656) and ACROBAT Evolve (NCT03792555), established the dosing regimen and demonstrated sustained biochemical control over extended treatment periods.

What Is the Current Prescriber Adoption?

Since launch, 263 unique healthcare providers have prescribed Palsonify. The 232 enrollment forms received during Q1 2026 indicate continued patient uptake and prescriber interest.

Patient access has improved, with approximately 70% of patients on reimbursed therapy by quarter-end. This represents progress in securing payer coverage for the oral therapy.

What Does This Mean for Business Development Teams?

The strong revenue trajectory and prescriber adoption suggest Palsonify is gaining traction in the acromegaly market. Business development teams should consider several factors when evaluating Crinetics' competitive position:

• The doubling of quarter-over-quarter sales indicates effective commercial execution and market demand for an oral alternative to injectable somatostatin analogs.
• The 263 prescriber count within two quarters of launch demonstrates rapid penetration among endocrinologists.
• Improved reimbursement rates (70%) suggest payer negotiations are progressing favorably.
• Crinetics' substantial cash position ($1.3 billion) provides runway for expanding commercial infrastructure and advancing pipeline programs.

What Are Crinetics' R&D and Expense Trends?

Research and development expenses increased to $100.1 million in Q1 2026, compared to $76.2 million in Q1 2025. The increase reflects advancement of clinical and preclinical programs beyond Palsonify.

Selling, general, and administrative expenses were $50.8 million in Q1 2026, up from $35.5 million in Q1 2025. This reflects investments in commercial infrastructure to support the Palsonify launch.

The company reported a net loss of $127.8 million for the quarter, compared to $96.8 million in the prior-year period. Increased operating expenses in support of commercialization drove the larger loss.

Frequently Asked Questions

Primary Sources

1. Crinetics Pharmaceuticals Q1 2026 Earnings Release — SEC Filing. SEC.gov
2. FDA Approves New Treatment for Acromegaly — FDA News Release, September 25, 2025. FDA.gov
3. Paltusotine for Acromegaly Phase 3 Trial — ClinicalTrials.gov Identifier: NCT04837040
4. ACROBAT Edge Phase 2 Study — ClinicalTrials.gov Identifier: NCT03789656
5. FDA Approval Letter for Paltusotine — Drugs@FDA NDA 219070

Related profiles

• PALSONIFY (Paltusotine)
• Crinetics Pharmaceuticals
• Acromegaly

Related coverage

• EMA Orphan Drug Designation Updates — 2025 Review
• Endocrine Disorders Market Outlook 2026
• Pituitary Disease Treatment Innovations